Brief: Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra™ Trial In Knee Osteoarthritis
04/03/2025 21:51
March 4 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA: ENLIVEX THERAPEUTICS ANNOUNCES INVESTOR WEBINAR TO DISCUSS POSITIVE INTERIM DATA FROM PHASE I/II ALLOCETRA™ TRIAL IN KNEE OSTEOARTHRITIS Source text: ID:nGNX8srGDQ Further company coverage: ENLV.TA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment